Invokana (Invokamet and Farxiga)
The drug is designed and manufactured to treat and lower blood sugar in patients suffering from Type 2 diabetes mellitus (DB). It is within a class of drugs known as SGLT2 inhibitors.
Increased risk of Diabetic Ketoacidosis, Kidney Failure and Cardiovascular Injuries involving hospitalizations and other serious complications such as diabetic comas, brain swelling and death.
In May 2015, the FDA issued a warning that the use of this class of medications may result in a serious condition involving too much acid in the blood. The result of too much acid in the blood can lead to kidney damage and other medical conditions.